Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Friday. The company traded as low as $14.11 and last traded at $14.30, with a volume of 5,236 shares trading hands. The stock had previously closed at $14.88.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on AAPG. Citigroup began coverage on Ascentage Pharma Group International in a research note on Wednesday, October 14th. They issued a “buy” rating and a $46.00 price objective on the stock. JPMorgan Chase & Co. reduced their target price on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a research note on Thursday, October 8th. Citizens Jmp initiated coverage on Ascentage Pharma Group International in a research report on Tuesday, October 13th. They issued a “market outperform” rating and a $35.00 price objective on the stock. BTIG Research restated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Finally, William Blair initiated coverage on shares of Ascentage Pharma Group International in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the company. According to data from MarketBeat, Ascentage Pharma Group International has a consensus rating of “Buy” and a consensus target price of $43.90.
Read Our Latest Stock Analysis on AAPG
Ascentage Pharma Group International Stock Performance
The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09. The company has a fifty day moving average price of $15.91 and a 200-day moving average price of $20.27.
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The company had revenue of $22.24 million during the quarter. As a group, equities analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 EPS for the current fiscal year.
About Ascentage Pharma Group International
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.
Featured Articles
- Five stocks we like better than Ascentage Pharma Group International
- Breaching the Valuation: The Real Reason Fortinet Dropped
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
- Silicon Shock: Intel’s 25% Valuation Reset
- Advanced Micro Devices’ Meta Platforms Partnership Goes Beyond a $1 Billion Investment
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
